Lemakalim, a potassium channel agonist, reverses electrophysiological impairments induced by a large dose of bupivacaine in anaesthetized dogs

Br J Anaesth. 1993 Oct;71(4):534-9. doi: 10.1093/bja/71.4.534.

Abstract

We have examined the ability of lemakalim to correct bupivacaine-induced cardiac electrophysiological impairment in an experimental electrophysiological model in closed-chest dogs. Two groups (n = 6) of pentobarbitone-anaesthetized dogs were given atropine 0.2 mg kg-1 i.v., and bupivacine 4 mg kg-1 i.v. over 10 s. Group 2 received also lemakalim 0.03 mg kg-1 i.v. Bupivacaine induced bradycardia, prolonged PR and His-ventricle (HV) intervals, QRS duration, QTc and JTc intervals, decreased left ventricular (LV) dP/dt max and increased LV end-diastolic pressure. Lemakalim reversed bupivacaine-induced PR, HV, QRS, QTc and JTc prolongation, and did not worsen bupivacaine-induced bradycardia and haemodynamic depression. We conclude that lemakalim can antagonize the main deleterious electrophysiological effects induced by a large dose of bupivacaine in anaesthetized dogs.

Publication types

  • Comparative Study

MeSH terms

  • Anesthesia, General
  • Animals
  • Atropine / pharmacology
  • Benzopyrans / pharmacology*
  • Bupivacaine / antagonists & inhibitors*
  • Cromakalim
  • Dogs
  • Electrocardiography / drug effects
  • Female
  • Heart / drug effects*
  • Heart Rate / drug effects
  • Male
  • Potassium Channels / drug effects
  • Pyrroles / pharmacology*
  • Time Factors

Substances

  • Benzopyrans
  • Potassium Channels
  • Pyrroles
  • Cromakalim
  • Atropine
  • Bupivacaine